© 2025 MJH Life Sciences™ , Patient Care Online – Primary Care News and Clinical Resources. All rights reserved.
Latest Conference Articles
Tirzepatide Treatment Leads to Weight Loss of up to 22.5% in SURMOUNT-1 Clinical Trial
June 4th 2022
ADA 2022: Tirzepatide led overall to weight loss of up to 22.5% of baseline body weight with persons taking the 15 mg dose losing an average of 52 pounds.
Tirzepatide Slows Renal Decline in T2D Patients with CKD in First Analysis of Dual Agent on Kidney Function
June 3rd 2022
ADA 2022: Tirzepatide, a GIP/GLP-1 receptor agonist, reduced a composite of kidney events in patients with type 2 diabetes and at increased cardiovascular risk in an analysis of SURPASS-4.
NAVIGATOR: Tezepelumab Reduces Asthma Exacerbations by More than Half
May 20th 2022
In our latest podcast episode, Njira Lugogo, MD, discusses NAVIGATOR data she presented at ATS 2022 that showed clinical responses to treatment with tezepelumab.
.jpg?fit=crop&auto=format)
Review of Biologic Treatments for Asthma Finds Inconsistent Effects on Airway Hyperresponsiveness
May 19th 2022
ATS 2022: Findings from a literature review provide insight into the mechanisms of airway hyperresponsiveness in asthma.
Tezepelumab Reduces Asthma Exacerbations by More than Half, Reports NAVIGATOR Study Author
May 19th 2022
Njira Lugogo, MD, sat down with Patient Care Online to discuss findings from the prespecified exploratory analysis of the NAVIGATOR study that she presented at ATS 2022.
Real-world Data Showed Mepolizumab Reduced Exacerbations, Oral Corticosteroid Use in Adults with Severe Asthma
May 18th 2022
ATS 2022: Mepolizumab was effective in reducing asthma exacerbations and oral corticosteroid use in real-world clinical practice, according to new research.
Novel PDE4B Inhibitor Slows Lung Function Decline in IPF: Phase 2 Data from Boehringer Ingelheim
May 17th 2022
ATS 2022: The investigational PDE4B inhibitor slowed pulmonary decline in patients with IPF, both alone and with background use of approved antifibrotics.
NAVIGATOR Data Presented at ATS 2022 Show Improved Clinical Responses to Treatment with Tezepelumab vs Placebo
May 16th 2022
ATS 2022. A greater proportion of tezepelumab-treated patients with severe, uncontrolled asthma achieved on-treatment clinical responses than placebo-treated patients.
Novel Fixed-dose Albuterol-Budesonide Inhaler Significantly Reduced Exacerbation Risk in Severe Asthma
May 16th 2022
ATS 2022: A fixed dose SABA/corticosteroid combination reduced risk of exacerbation by 27% vs SABA alone in the MANDALA study.
Objective Confirmation of Asthma Diagnosis Often Missing in Primary Care, Study Suggests
May 14th 2022
ATS 2022: Charts from an EHR that included a suspected diagnosis of asthma either had no objective documentation or mentioned a test but included no results.